HDAC6 and cancer: Inhibiting HDAC6 function is postulated to have therapeuticbenefitsin a number of different cancers, neurodegenerative diseases, andother pathologies.12−14 To date, HDAC6 drug discovery has focused on inhibitorstargeting the catalytic activity of this protein and is currentlybeing tested in the clinic, in some cases in combination with proteasomeinhibitors.15−18 HDAC6 catalytic inhibitors prevent the deacetylation of microtubules,which disrupts dynein-mediated transport of protein cargoes to theaggresome.